Pharmaceuticals
-
Sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products
Jun 24, 2016News Hour: Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced results from two key studies comparing its biosimilar etanercept and rituximab candidates with the originator products – Enbrel® and MabThera® respectively. In both... -
Data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV)
Jun 24, 2016News Hour: Novartis announced Phase III data from RESPONSE-2 showing that Jakavi®(ruxolitinib) helped patients with polycythemia vera (PV), who did not have an enlarged spleen and were resistant to or intolerant of hydroxyurea, achieve superior hematocrit... -
Timely use of Novartis’ Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients
Jun 24, 2016News Hour: A new analysis published in JAMA Cardiology has found that timely and broad adoption of Entresto® (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than... -
Roche launches the new cobas e 801 module
Jun 20, 2016News Hour: Roche announced today that its new, dedicated high-volume testing immunoassay solution, the cobas e 801 module, is now available for countries accepting the CE Mark. As diagnostic laboratories evolve to meet growing workloads in an...
